Literature DB >> 2236023

Steroids induce acetylcholine receptors on cultured human muscle: implications for myasthenia gravis.

I Kaplan1, B T Blakely, G K Pavlath, M Travis, H M Blau.   

Abstract

Antibodies to the acetylcholine receptor (AChR), which are diagnostic of the human autoimmune disease myasthenia gravis, block AChR function and increase the rate of AChR degradation leading to impaired neuromuscular transmission. Steroids are frequently used to alleviate symptoms of muscle fatigue and weakness in patients with myasthenia gravis because of their well-documented immunosuppressive effects. We show here that the steroid dexamethasone significantly increases total surface AChRs on cultured human muscle exposed to myasthenia gravis sera. Our results suggest that the clinical improvement observed in myasthenic patients treated with steroids is due not only to an effect on the immune system but also to a direct effect on muscle. We propose that the identification and development of pharmacologic agents that augment receptors and other proteins that are reduced by human genetic or autoimmune disease will have broad therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2236023      PMCID: PMC54900          DOI: 10.1073/pnas.87.20.8100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

1.  Acetylcholine receptor degradation measured by pulse chase labelling.

Authors:  J P Merlie; J P Changeux; F Gros
Journal:  Nature       Date:  1976-11-04       Impact factor: 49.962

2.  Induction of choline phosphotransferase and lecithin synthesis in the fetal lung by corticosteroids.

Authors:  P M Farrell; R D Zachman
Journal:  Science       Date:  1973-01-19       Impact factor: 47.728

3.  Development of hormone receptors and hormonal responsiveness in vitro. Insulin receptors and insulin sensitivity in the preadipocyte and adipocyte forms of 3T3-L1 cells.

Authors:  C S Rubin; A Hirsch; C Fung; O M Rosen
Journal:  J Biol Chem       Date:  1978-10-25       Impact factor: 5.157

Review 4.  The course of myasthenia gravis and therapies affecting outcome.

Authors:  D Grob; E L Arsura; N G Brunner; T Namba
Journal:  Ann N Y Acad Sci       Date:  1987       Impact factor: 5.691

5.  Effect of calcitonin and glutocorticoids in combination on the hypercalcemia of malignancy.

Authors:  M L Binstock; G R Mundy
Journal:  Ann Intern Med       Date:  1980-08       Impact factor: 25.391

6.  The acetylcholine receptors of human muscles are not stained with rhodamine-labeled erabutoxin-b.

Authors:  Y Ishikawa; Y Shimada
Journal:  Brain Res       Date:  1983-04-25       Impact factor: 3.252

7.  Antigenic modulation of human myotube acetylcholine receptor by myasthenic sera. Serum titer determines receptor internalization rate.

Authors:  S J Tzartos; D Sophianos; K Zimmerman; A Starzinski-Powitz
Journal:  J Immunol       Date:  1986-05-01       Impact factor: 5.422

8.  Antibodies from myasthenic patients that compete with cholinergic agents for binding to nicotinic receptors.

Authors:  B W Fulpius; R Miskin; E Reich
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

9.  Dexamethasone effects on myoblast proliferation and differentiation.

Authors:  V Guerriero; J R Florini
Journal:  Endocrinology       Date:  1980-04       Impact factor: 4.736

10.  Myasthenic immunoglobulin accelerates acetylcholine receptor degradation.

Authors:  I Kao; D B Drachman
Journal:  Science       Date:  1977-04-29       Impact factor: 47.728

View more
  9 in total

Review 1.  Juvenile myasthenia: diagnosis and treatment.

Authors:  B Anlar
Journal:  Paediatr Drugs       Date:  2000 May-Jun       Impact factor: 3.022

Review 2.  Myasthenia gravis as a prototype autoimmune receptor disease.

Authors:  A C Hoedemaekers; P J van Breda Vriesman; M H De Baets
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

3.  Development of an assay for modulating anti-acetylcholine receptor autoantibodies using human rhabdomyosarcoma cell line.

Authors:  B W Lyons; L L Wu; M E Astill; J T Wu
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

4.  Modulation by prednisolone of calcium handling in skeletal muscle cells.

Authors:  L Metzinger; A C Passaquin; W J Leijendekker; P Poindron; U T Rüegg
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

5.  Ocular myasthenia gravis: controversies and updates.

Authors:  Sui H Wong; Saif Huda; Angela Vincent; Gordon T Plant
Journal:  Curr Neurol Neurosci Rep       Date:  2014-01       Impact factor: 5.081

6.  Complete resistance after maximal dose of rocuronium.

Authors:  Annalisa Capuano; Maria Giuseppa Sullo; Concetta Rafaniello; Liberata Sportiello; Pierfrancesco Fusco; Macella De Vizia; Fausto Ferraro
Journal:  J Pharmacol Pharmacother       Date:  2015 Jul-Sep

7.  Uncoupling of growth inhibition and differentiation in dexamethasone-treated human rhabdomyosarcoma cells.

Authors:  C De Giovanni; P L Lollini; R Dolcetti; L Landuzzi; G Nicoletti; E D'Andrea; K Scotland; P Nanni
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

8.  Myasthenia Gravis and Associated Diseases.

Authors:  Nikolina Tanovska; Gabriela Novotni; Slobodanka Sazdova-Burneska; Igor Kuzmanovski; Bojan Boshkovski; Goran Kondov; Marija Jovanovski-Srceva; Anita Kokareva; Rozalinda Isjanovska
Journal:  Open Access Maced J Med Sci       Date:  2018-03-05

9.  Effect of protracted dexamethasone exposure and its withdrawal on rocuronium-induced neuromuscular blockade and sugammadex reversal: an ex vivo rat study.

Authors:  Seok Kyeong Oh; Byung Gun Lim; Sungsoo Park; Hong Seuk Yang; Junyong In; Yong Beom Kim; Hey-Ran Choi; Il Ok Lee
Journal:  Sci Rep       Date:  2019-08-02       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.